A 10-Minute Urine Test for Dementia Risk — and the Diagnostics Market It Could Reshape

One Step Dementia Risk Test Kit

A rapidly aging population has exposed a gap in the global diagnostic infrastructure for dementia. Current gold-standard detection methods — PET imaging and CSF analysis — are expensive, invasive, and confined to specialist centers. Chronic underdiagnosis follows, particularly in primary care settings where early-stage cognitive decline is often missed or attributed to normal aging.

The One Step Dementia Risk Test Kit, a colloidal gold lateral immunochromatography product, occupies this gap. It detects urinary beta-amyloid (Aβ) concentration — a well-established hallmark of Alzheimer’s pathology — using a fresh midstream urine sample of just 100 microliters. Its reported sensitivity is 79.14 percent, specificity 91.03 percent, with a Kappa value of 0.704, indicating substantial agreement with clinical reference standards.

Clinically, it functions as an auxiliary screening tool for risk alert rather than a standalone diagnostic. For patients aged 45 and above — particularly those with cardiovascular comorbidities, family history of dementia, or lifestyle risk factors — it provides a low-cost, low-friction triage point. Positive results justify further workup, reducing unnecessary referrals while flagging high-risk individuals earlier.

The operational significance lies in what the kit removes: the cold chain, the venipuncture, the lab scheduling. A community clinic or mobile screening unit can store the test at room temperature, administer it on-site, and get a readout before the patient leaves. That changes workflow economics, particularly in rural or under-resourced health systems where access to neurology specialists is limited.

Manufactured under CE, NMPA, and MDA certification, the kit relies on a proprietary Aβ monoclonal antibody and an antibody-polymer sandwich method — a technical approach that the manufacturer has developed in-house. This suggests a vertically integrated supply chain for the core reagent, reducing dependency on imported biological materials and stabilizing cost and availability for procurement teams.

From a procurement perspective, the kit meets a clear demand signal: packaged in boxes of 1, 25, or 50 tests, it is designed for both single-use evaluation and batch screening in corporate wellness or government-funded health checks. For a hospital supply officer, the decision is less about clinical novelty and more about whether this test can reliably offload burden from radiology and neurology departments.

If widely adopted, the One Step kit could shift dementia screening from a specialist referral to a routine panel — much like rapid glucose or cholesterol tests did for metabolic disease. The infrastructure to run it already exists; the question is whether health systems will integrate it before the dementia wave arrives.

Why it matters:
For procurement teams and health system operators, this kit represents a practical route to earlier population-level screening — without the capital expenditure of advanced imaging. Its in-house antibody manufacturing also points to a growing domestic capability in diagnostic reagent production that reduces import risk.

View Product →